Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides
13 Dezember 2021 - 6:00PM
Business Wire
- Adocia's technology has shown promising in vivo results with
the oral administration of a GLP-1 receptor agonist for the
treatment of diabetes
- First-in-Human clinical study planned for 2022 to establish
proof of concept
- The potential of this technology is being assessed across
different therapeutic peptides and proteins
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage
biopharmaceutical company focused on diabetes treatments and other
metabolic diseases with innovative formulations of peptides and
proteins, announced today the filing of a patent for an oral
delivery technology of peptides.
Peptides and proteins are widely used as drugs, especially in
the treatment of chronic diseases such as diabetes. However, almost
all these drugs are only available in injectable dosage forms,
which represents a burden for patients and limits the adoption of
these products, especially in chronic diseases that require
numerous and regular injections. In recent years, intense research
efforts have focused on developing oral dosage forms. However,
there are considerable technological challenges as peptides are not
naturally absorbed in the digestive tract and undergo significant
degradation before entering the bloodstream.
Adocia has developed a formulation which has demonstrated
through preclinical studies an enhancement of the efficiency of
peptide absorption by the digestive tract, making it possible to
switch from injectable to oral dosage forms.
"We are pleased to add this third technology platform to our
portfolio. It opens up a number of applications in markets we know
well, such as diabetes and obesity," said Gérard Soula, President
& CEO of Adocia. "We plan to conduct a first-in-human clinical
study in 2022 to validate the proof of concept”.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic peptides and proteins for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring six clinical-stage products and several
pre-clinical products.
Adocia’s clinical pipeline includes five novel insulin
formulations for the treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and two combinations of a
prandial insulin with amylin analog pramlintide (M1Pram and
BioChaperone® LisPram). The clinical pipeline also includes an
aqueous formulation of human glucagon (BioChaperone® Glucagon) for
the treatment of hypoglycemia.
Adocia’s preclinical pipeline includes bi-hormonal combinations
for diabetes treatment: a combination of aspart rapid acting
insulin analog and pramlintide (BioChaperone® AsPram), a
combination of insulin glargine with GLP-1 receptor agonist
(BioChaperone® Glargine Liraglutide). In addition, there are three
multi-hormonal products for the treatment of obesity: a combination
of glucagon and exenatide (BioChaperone® GluExe), a combination of
pramlintide and exenatide (PramExe) and a triple combination of
pramlintide glucagon exenatide (BioChaperone® PramGluExe).
Adocia's portfolio is based on three technology platforms: 1)
The BioChaperone® platform is designed to enhance the effectiveness
and/or safety of therapeutic proteins while making them easier for
patients to use; 2) A platform designed to improve cell therapy
techniques using a hydrogel matrix; 3) A platform for the oral
delivery of peptides.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those which are set forth
in the “Risk Factors” section of the universal registration
document that was filed with the French Autorité des marchés
financiers on April 20, 2021 (a copy of which is available at
www.adocia.com), in particular uncertainties that are linked to
research and development, future clinical data, analyses, and the
evolution of the economic context, the financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not considered as material by Adocia as of this
day. The occurrence of all or part of such risks could cause that
actual results, financial conditions, performances, or achievements
of Adocia be materially different from those mentioned in the
forward-looking statements. This press release and the information
contained herein do not constitute an offer to sell or the
solicitation of an offer to buy Adocia’s shares in any
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211213005672/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com
Ph: +33 4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund Gabriel,
Shaun Brown, Andreas Jungfer adocia@mc-services.eu Ph: +49 89
210 228 0
Adocia (EU:ADOC)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Adocia (EU:ADOC)
Historical Stock Chart
Von Apr 2023 bis Apr 2024